Search results
AbbVie lifts profit forecast after Skyrizi sales beat expectations
AOL· 6 days ago(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street ...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 7 days agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 6 days ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 14 hours agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ...
GuruFocus.com via Yahoo Finance· 5 days agoTotal Net Revenues: $12.3 billion, $400 million ahead of expectations. Ex-Humira Growth Platform Revenue Growth: Over 15% this quarter. Skyrizi and Rinvoq Combined Growth: ...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 2 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 5 days agoBut AbbVie stock fell all the same, closing Friday's session down by 4.6%, capping off more than a...
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks via Yahoo Finance· 5 days agoSales rose 0.7% year over year on a reported basis and 1.6% on an operational basis. The upside can...
AbbVie’s first-quarter results top expectations as arthritis drugs fuel growth
Market Watch· 6 days agoAbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of...
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 6 days agoAlthough that has meant Humira’s market share dropped from 96% to 81% over two weeks, Stewart said...